SWITZERLAND'S AC IMMUNE OPENS FOR TRADING ON NASDAQ
Lausanne, Switzerland, September 23, 2016 - AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that its common shares will open for trading on the NASDAQ Stock Market under the ticker symbol "ACIU" following its initial public offering in which it raised net proceeds of approximately USD 57.8 million (CHF 56.5 million*). CEO Prof. Andrea Pfeifer will be joined by members of AC Immune's senior team and guests at the First Trade Ceremony at NASDAQ's headquarters in New York.
Professor Andrea Pfeifer, CEO of AC Immune said: "We are delighted to take AC Immune public and to join NASDAQ, the right trading platform for our company as we broaden our shareholder base to support our next growth phase. With our pipeline of seven therapeutic and three diagnostic candidates, we believe that we are well-positioned to leverage our expertise in addressing Alzheimer's disease and other disorders caused by misfolding proteins."
"I wish to thank all of our employees, founders, board members, shareholders, business partners and members of the medical community for their loyalty and support which has enabled us to achieve the maturity of a public company ", she concluded.
Martin Velasco, Chairman of the Board, commented: "AC Immune has made remarkable progress since its foundation in 2003, benefiting from the vibrant life science and business environment in Switzerland. Today marks broader international recognition of the company, and we welcome our new investors in Switzerland, the United Kingdom, the United States and elsewhere as we pursue our goal of becoming a leader in personalized treatments for neurodegenerative diseases."
The live webcast of the First Trade Ceremony with Prof. Andrea Pfeifer can be viewed at 10:00am EDT (4:00pm CEST) please click here.
About AC Immune
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins.
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these statements. Forward-looking statements include information concerning the offering. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that we will affect the offering. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
For further information please contact:
| Prof. Andrea Pfeifer |
Chief Executive Officer
Phone: +41-21-345 91 21
| Eva Schier |
Corporate Communications Manager
Phone: +41-21-345 91 34
Mobile: +41 79 926 66 03
| Nick Miles/ Toomas Kull |
Cabinet Privé de Conseils s.a.
Phone : +41 22 321 45 40
E-mail : firstname.lastname@example.org
| In the US |
The Communications Strategy Group Inc.
Phone: +1 781 631 3117